Literature DB >> 17492420

[Dementia with Lewy bodies. Clinical improvement under treatment with an acetylcholinesterase inhibitor].

M Omerovic1, S J Teipel, T Hampel.   

Abstract

Dementia with Lewy Bodies (DLB) is the second most common form of dementia in the elderly. Core features of the DLB are fluctuating cognitive symptoms, visual hallucinations and spontaneous parkinsonism. The clinical diagnostic criteria are very useful in the differentiation between DLB and Alzheimer's disease. The deficits in cholinergic neurotransmission are pronounced and associated with cognitive and psychotic symptoms. An 83 years old patient with DLB showed well formed recurrent visual hallucinations and fluctuating cognition and attention. There was no response to treatment with atypical neuroleptics. The patient responded within few days to treatment with Donepezil. Both cognitive and behavioural symptoms were improved significantly.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17492420     DOI: 10.1007/s00115-007-2277-1

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  26 in total

1.  Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease.

Authors:  E K Perry; I McKeith; P Thompson; E Marshall; J Kerwin; S Jabeen; J A Edwardson; P Ince; G Blessed; D Irving
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

2.  Tacrine efficacy in Lewy body dementia.

Authors:  F Lebert; F Pasquier; L Souliez; H Petit
Journal:  Int J Geriatr Psychiatry       Date:  1998-08       Impact factor: 3.485

3.  Fluctuations in attention: PD dementia vs DLB with parkinsonism.

Authors:  C G Ballard; D Aarsland; I McKeith; J O'Brien; A Gray; F Cormack; D Burn; T Cassidy; R Starfeldt; J-P Larsen; R Brown; M Tovee
Journal:  Neurology       Date:  2002-12-10       Impact factor: 9.910

4.  Motor and cognitive function in Lewy body dementia: comparison with Alzheimer's and Parkinson's diseases.

Authors:  K K Gnanalingham; E J Byrne; A Thornton; M A Sambrook; P Bannister
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

5.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.

Authors:  M Baba; S Nakajo; P H Tu; T Tomita; K Nakaya; V M Lee; J Q Trojanowski; T Iwatsubo
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

6.  Delusions associated with elevated muscarinic binding in dementia with Lewy bodies.

Authors:  C Ballard; M Piggott; M Johnson; N Cairns; R Perry; I McKeith; E Jaros; J O'Brien; C Holmes; E Perry
Journal:  Ann Neurol       Date:  2000-12       Impact factor: 10.422

7.  Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.

Authors:  I McKeith; T Del Ser; P Spano; M Emre; K Wesnes; R Anand; A Cicin-Sain; R Ferrara; R Spiegel
Journal:  Lancet       Date:  2000-12-16       Impact factor: 79.321

8.  Cholinergic and dopaminergic activities in senile dementia of Lewy body type.

Authors:  E K Perry; E Marshall; R H Perry; D Irving; C J Smith; G Blessed; A F Fairbairn
Journal:  Alzheimer Dis Assoc Disord       Date:  1990       Impact factor: 2.703

9.  The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.

Authors:  J L Cummings; M Mega; K Gray; S Rosenberg-Thompson; D A Carusi; J Gornbein
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

10.  Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients.

Authors:  C Shea; C MacKnight; K Rockwood
Journal:  Int Psychogeriatr       Date:  1998-09       Impact factor: 3.878

View more
  1 in total

Review 1.  Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases.

Authors:  P R Bharadwaj; K A Bates; T Porter; E Teimouri; G Perry; J W Steele; S Gandy; D Groth; R N Martins; Giuseppe Verdile
Journal:  Transl Psychiatry       Date:  2013-12-03       Impact factor: 6.222

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.